SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis

Ruben A. Mesa, Jean‐Jacques Kiladjian, John Catalano, +11

Journal of Clinical Oncology

Hematological MalignancyImmunohematologyMomelotinib 200Health SciencesPediatric Hematology +11

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

Claire Harrison, Alessandro M. Vannucchi, Uwe Platzbecker, +10

The Lancet Haematology

Hematological MalignancyMomelotinib VersusSimplify 2HematologyPharmacotherapy +3

Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma

Raffit Hassan, Hedy L. Kindler, Thierry Jahan, +9

Clinical Cancer Research

Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease

Daniel J. O’Shannessy, Elizabeth B. Somers, Julia D. Maltzman, +2

SpringerPlus

Breast OncologyPathologyCancer BiologyTumor BiologyOncology +14

Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors

Brian M. Necela, Jennifer A. Crozier, Cathy Andorfer, +15

PLoS ONE

Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study

Manish A. Shah, Alexander Starodub, Sunil Sharma, +14

Clinical Cancer Research

Significance of Folate Receptor Alpha and Thymidylate Synthase Protein Expression in Patients with Non–Small-Cell Lung Cancer Treated with Pemetrexed

Daniel C. Christoph, Bernadette Reyna Asuncion, Biftu Hassan, +10

Journal of Thoracic Oncology

MedicineFolate Receptor AlphaPathologyCancer BiologyCancer Treatment +4

A phase 2 study of simtuzumab in patients with primary, post‐polycythaemia vera or post‐essential thrombocythaemia myelofibrosis

Srđan Verstovšek, Michael R. Savona, Ruben A. Mesa, +6

British Journal of Haematology

Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging

Liza Lindenberg, Anish Thomas, Stephen Adler, +9

Oncotarget

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia

Srđan Verstovšek, Stéphane Courby, Martin Grießhammer, +8

Leukemia Research